As targeted therapies have opened up precision medicine approaches to cancer treatment, oncologists and patients are increasingly moving to liquid biopsy as a front-line diagnostic approach to detection of actionable mutations to enable faster treatment decisions. Mutation detection in ctDNA has been shown to highly correlate to tissue biopsy for making treatment decisions, faster results and has the additional advantage of simplified specimen collection. Liquid biopsy represents an emerging paradigm shift in oncology practice and this session will discuss its promise and challenges from the Pharma, biotech and medical affairs perspectives.
Rebecca Brandes is a member of the Companion Diagnostics (CDx) Division specializing in Oncology Market Development at Agilent. This team is charged with the objective to help with the education and consultation on advanced genomic technologies for use in CDx including expertise in genomic technologies, clinical laboratory workflows, current testing methodologies and paradigms and genetics and oncology. Joining Agilent in 2014 with 18 years of expertise gained from leadership roles, her background includes CLIA-CAP lab operations, developing and submitting products for regulation, developing integrated workflows for routine testing and business development for companion diagnostics with an emphasis on Oncology. She holds degrees from High Point University in Biology, Biochemistry and Anthropology and a master's in Molecular Genetics from Wake Forest University. Prior to joining QIAGEN, Asuragen, Affymetrix, Stanford’s StartX not-for-profit accelerator and Agilent to lead their marketing organizations, Rebecca spent several years running a high-throughput, CAP/CLIA clinical molecular oncology laboratory.
Dr. Anderes has worked in a variety of roles that were initially the precursors to today’s Precision Medicine including a number of senior executive/scientific advisory positions at pharmaceutical, biotech and medical device companies. Dr. Anderes acquired very broad, interdisciplinary technical, regulatory and business skills, with an extensive knowledgebase in clinical research, and vitro diagnostic device development. Achievements range from lead identification of new molecular entities to characterization of clinical development candidates for several distinct first in class molecular targeted agents to treat cancer. In parallel to drug discovery/development activities, Dr. Anderes has lead equally diverse biomarker and companion diagnostic projects from biological validation to clinical trial assay development to regulatory approval roadmaps across multiple platform technologies. She has been involved in the development of state of the art liquid biopsy approaches to evaluate clinical utility of CTCs and ctDNA.
Dr. Kate Knobil joined Agilent in April 2021 as the company’s first Chief Medical Officer and is helping to expand Agilent’s leadership in precision medicine and the development of novel therapeutics to improve patient outcomes. Kate has more than 20 years of experience in clinical development and medical affairs while serving in global strategic leadership roles. Prior to joining Agilent, Kate was CMO and head of R&D at Kaleido Biosciences, applying her pharmaceutical experience to help translate the promise of the microbiome into solutions for patients. Prior to Kaleido, Kate served in a variety of leadership roles at GlaxoSmithKline, including head of late-stage clinical development in China, head of value evidence and outcomes, and CMO.